CLDX vs CTMX: fair value comparison
Celldex Therapeutics, Inc. and CytomX Therapeutics, Inc. · Updated 2026-10-19
CLDX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CTMX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CLDX currently ranks higher by quality score.
| CLDX | CTMX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $27.53 | $2.28 |
| 12-month range | $22.58–$44.87 | $2.23–$6.75 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #182 of 301 Healthcare | #183 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: CLDX fair value analysis · CTMX fair value analysis